The scale and impact of mental illness across society is huge. One in ten children, and one in four adults (approx. 15 million people) experience mental illness each year, affecting their wellbeing, relationships, and potential ability to work. The economic and social cost has been estimated as £105bn a year in England alone. New treatments are needed urgently. However, the lack of novel drug targets combined with the challenge of validating them pre-clinically, and the high failure rate in clinical trials have led to a reduced investment in drug discovery and development in the last decade and there have been no new effective types of treatment for over 30 years.
What we’re looking for
The Psychiatry Consortium is seeking project proposals which focus on the validation of novel molecular drug-targets for the following mental health conditions:
psychotic disorders, bipolar disorder, depression, anxiety, stress-related disorders, PTSD, OCD, autism spectrum disorders as well as psychiatric symptoms associated with dementia and other cognitive disorders
The Psychiatry Consortium intend to fund projects which:
- show some evidence that links the molecular target to human disease and of the target modulation having a therapeutic effect, which can be further developed or validated
- will enable tools for target validation e.g. through optimisation of existing tool compounds to improve selectivity, potency, bioavailability
Projects seeking to identify target modulation biomarkers relevant to disease will also be in scope.
What we will offer:
The research projects we support are collaborative in nature, with involvement from the Psychiatry Consortium members in devising the final project plan.
The Psychiatry Consortium will provide the successful applicants access to:
- drug-discovery expertise
- drug-discovery capabilities, through specialised Partner Organisations
- commercial know-how
- project management resources
- project funding
For more information click “LINK TO ORIGINAL” below.